Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

GLP-1 improves neuropathology after murine cold lesion brain trauma

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Consistent improvement with eculizumab across muscle groups in myasthenia gravis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Responsiveness of outcome measures in myotonic dystrophy type 1

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Global FKRP Registry: observations in more than 300 patients with Limb Girdle Muscular Dystrophy R9

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. No effect of triheptanoin on exercise performance in McArdle disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Natural history of limb girdle muscular dystrophy R9 over 6 years: searching for trial endpoints

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Infectious diseases detected by screening after arrival to Denmark in internationally adopted children

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Critical evaluation of the appetite test for children with severe acute malnutrition

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVES: In this study, we address a gap in knowledge regarding the therapeutic potential of acute treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist after severe brain trauma. Moreover, it remains still unknown whether GLP-1 treatment activates the protective, anti-neurodegenerative cAMP response element binding protein (CREB) pathway in the brain in vivo, and whether activation leads to observable increases in protective, anti-neurodegenerative proteins. Finally, we report the first use of a highly sensitive in vivo imaging agent to assess reactive species generation after brain trauma.

METHODS: Severe trauma was induced with a stereotactic cryo-lesion in mice and thereafter treated with vehicle, liraglutide, or liraglutide + GLP-1 receptor antagonist. A therapeutic window was established and lesion size post-trauma was determined. Reactive oxygen species were visualized in vivo and quantified directly ex vivo. Hematological analysis was performed over time. Necrotic and apoptotic tone and neuroinflammation was assessed over time. CREB activation and CREB-regulated cytoprotective proteins were assessed over time.

RESULTS: Lira treatment reduced lesion size by ∼50% through the GLP-1 receptor. Reactive species generation was reduced by ∼40-60%. Necrotic and apoptotic tone maintained similar to sham in diseased animals with Lira treatment. Phosphorylation of CREB was markedly increased by Lira in a GLP-1 receptor-dependent manner. CREB-regulated cytoprotective and anti-neurodegenerative proteins increased with Lira-driven CREB activation.

INTERPRETATION: These results show that Lira has potent effects after experimental trauma in mice and thus should be considered a candidate for critical care intervention post-injury. Moreover, activation of CREB in the brain by Lira - described for the first time to be dependent on pathology - should be investigated further as a potential mechanism of action in neurodegenerative disorders.

Original languageEnglish
JournalAnnals of Clinical and Translational Neurology
Volume1
Issue number9
Pages (from-to)721-32
Number of pages12
DOIs
Publication statusPublished - Sep 2014

ID: 44829054